A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients

Comba, Alberto Zori; Blajman, C.; Richardet, Eduardo; Bella, Sara Di; Vilanova, Manuel; Cóppola, Federico; Kooten, Maximiliano Van; Rodger, J.; Giglio, R.; Balbiani, L.; Perazzo, Florencia; Montiel, Maria Fernanda; Chacón, Matías; Pujol, F. Olivet; Mickiewicz, E.; Cazap, Eduardo; Recondo, Gonzálo; Lastiri, Francisco; Simon, Jody; Wasserman, Ernesto; Schmilovich, A.

doi:10.1016/s0959-8049(01)00080-6

Cited by 34 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OXA is a third-generation platinum drug, which inhibits DNA replication [46]. However, the obtained efficacy is suboptimal due to the aggressive side effects OXA and drug resistance of cancer cells [46][47][48]. The pro-apoptotic activities of NPs and OXA were analyzed by flow cytometry for both CT-26 and nontumor cells.…”

Section: Discussionmentioning

confidence: 99%

Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

Apoptosis signaling pathways, drug resistance, and metastasis are important targets to develop new cancer treatments. We developed cholesterol-coated Poly(d,l-Lactide-co-Glycolic Acid) (PLGA) nanoparticles for effective encapsulation and delivery of retinoic acid and oxaliplatin to analyze their antitumor activity in colorectal cancer. The cell viability and proliferation of tumoral cells lines (CT-26 and SW-480) decreased when compared to control in vitro after treatment with the nanoparticles. In addition, apoptosis of CT-26 cells increased. Importantly, cytoprotection of nontumor cells was detected. Expression of pro-apoptotic proteins was upregulated, while anti-apoptotic proteins were downregulated either in vitro or in vivo. In addition, drug resistance and metastasis factors were downregulated in vivo. Human colorectal tumors that highly expressed BCL-2 and Ki-67 had a greater tendency towards death within 60 months. Our results show that loading oxaliplatin combined with retinoic acid and cholesterol in a nanoparticle formulation enables determination of optimal antitumor activity and subsequent treatment efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Table 1 summarizes the reported incidence in various clinical trials in patients with advanced colorectal carcinoma who received a 2‐hour infusion of oxaliplatin in combination with 5‐FU/leucovorin 5–24. Based on these published results, the incidence was 0.55%.…”

Section: Methodsmentioning

confidence: 99%

Hypersensitivity and idiosyncratic reactions to oxaliplatin

Thomas¹,

Quinn²,

Schüler³

et al. 2003

Cancer

102

109

View full text Add to dashboard Cite

BACKGROUND Oxaliplatin is a third‐generation platinum analog that is used to treat a variety of solid tumors, particularly colorectal carcinoma. Patients may develop hypersensitivity reactions, although this complication occurs infrequently. METHODS Three patients developed hypersensitivity reactions to oxaliplatin while undergoing treatment on a Phase I trial of oxaliplatin and capecitabine. An Entrez PUBMED search was performed to identify other cases. RESULTS Two patients experienced the abrupt onset of erythema alone or with pruritis during the 9th and 11th infusions of oxaliplatin, whereas the other patient developed fever and mild dyspnea a few hours after the 9th oxaliplatin infusion. All 3 patients were rechallenged successfully for at least 1 additional oxaliplatin infusion by using oral dexamethasone, 20 mg orally, 6 and 12 hours before the administration of oxaliplatin and by administering intravenously 125 mg of solumedrol, 50 mg of diphenhydramine, and 50 mg of cimetidine 30 minutes before oxaliplatin. The literature review suggests two distinct patterns of reactions: classic hypersensitivity (as experienced by the first two patients) and idiosyncratic reactions (as experienced by the third patient). CONCLUSIONS Patients who develop mild to moderate hypersensitivity to oxaliplatin may be pretreated with steroids and antagonists of Type 1 and 2 histamine receptors, whereas patients who develop severe reactions are unlikely to tolerate further therapy. Cancer 2003;97:2301–7. Published 2003 American Cancer Society. DOI 10.1002/cncr.11379

show abstract

“…Oxaliplatin is a third‐generation 1,2‐DACH‐platinum compound that differs in clinical activity and toxicity profiles from other platinum derivatives and has shown efficacy in the systemic treatment of advanced CRC both as a single‐agent and in combination regimens. Although single‐agent oxaliplatin yielded only moderate response rates and short progression‐free survival in various Phase II trials, considerable improvement was obtained in combinations involving bolus or chronomodulated 5‐FU/LV 36–52. Combined schedules with capecitabine or UFT yielded comparable response rates (Table 1).…”

Section: Oxaliplatinmentioning

confidence: 99%